Search results for SN

Open search
Tenzing MEMO publishes independent research you won't find anywhere else. Sign up for a free trial to access everything — including 30 articles published in the last two weeks.
Sign Up
Vertex Pharmaceuticals Incorporated (VRTX)
Locked

The Kidney Franchise the Market Hasn't Priced

The familiar standoff—elite CF monopoly versus a full multiple and a maturing core—resolves in the buyers' favor once you weight the catalysts by how knowable they are. CF is converting toward ALYFTREK on a long exclusivity runway and funding everything else; that is the demon...

Read Article ›
Lumen Technologies, Inc. (LUMN)
Locked

The Solvency Trade Is Over, The Execution Trade Has Just Begun

Lumen is no longer the same company that frightened credit analysts two years ago. Strip away the legacy CenturyLink copper businesses and what remains is an enterprise and wholesale network operator built around three things: a 340,000 route mile fiber backbone, a fast growin...

Read Article ›
Tradeweb Markets Inc. (TW)

A Business Visibly Accelerating While the Share Price Retreats

The company is printing record revenue, expanding swaps share across every major currency, growing international past 40% of the mix, and converting more than $1 billion to free cash flow — yet the stock sits near a 52-week low because investors have fixated on a fee-per-milli...

Read Article ›
Tapestry, Inc. (TPR)
Locked

The Market Is Missing Something Big at Tapestry

Tapestry just delivered its most impressive quarter in over a decade. Coach constant-currency revenue rose 29%, and consolidated adjusted EPS of $1.66 beat consensus by roughly 27%. Management raised full-year guidance to approximately $7.95 billion in revenue and ~23% operati...

Read Article ›
Jack Henry & Associates, Inc. (JKHY)
Locked

Jack Henry's Best Quarter in Years and the Market Doesn't Care

Jack Henry & Associates (JKHY) is a quality financial technology compounder whose stock has been punished even as its business accelerates. Shares trade near 52-week lows — down roughly 31% from their January high of $193.39 — despite record Q3 results, a surge in competitive ...

Read Article ›